Buchang Pharma announced that two exclusive products, Kangfuyan Capsules and Mudan Granules, have been newly included in the 2026 edition of the National Essential Medicines List, which will take effect from September 1, 2026. The sales revenue of these two products in 2025 was 136 million yuan and 195 million yuan respectively. The company and its controlled subsidiaries have a total of 104 products included in the Essential Medicines List. In the first quarter of 2026, Buchang Pharma achieved revenue of 2.579 billion yuan and net profit attributable to the parent company of 320 million yuan.
Shandong Buchang Pharmaceuticals Co LtdTwo exclusive products newly added to National Essential Medicines List, expanding market access.